.. In the recently diagnosed subgroup, one male placebo-treated patient reported ejaculation disorder. In the overall study population, there was an additional report of one female patient in the paliperidone palmitate group who reported loss of libido (Figure 5). Figure 5. Prolactin-related adverse events

over entire study. One male patient with recently diagnosed schizophrenia treated with placebo reported ejaculation disorder during the entire study period. In the overall study population, there was one additional report … Efficacy during entire study There was a significant improvement from baseline in PANSS total score at endpoint in recently diagnosed patients who received paliperidone palmitate Inhibitors,research,lifescience,medical 150/100mgeq (234/156mg) compared with those who received placebo (Table 3). The effect size (versus placebo) based on the LS mean score change was –0.7 (95% CI –1.16 to –0.23; p=0.0031) in the recently diagnosed subgroup; it was –0.5 (95% CI –0.69 to –0.25; p<0.0001) in the overall study population. Inhibitors,research,lifescience,medical Table 3. PANSS, CGI-S, and PSP mean baseline, mean changes from baseline to endpoint and effect sizes: paliperidone palmitate versus placebo (95% confidence interval, p-value). In

the recently diagnosed subgroup, effect sizes for improvements in CGI-S and PSP with paliperidone palmitate compared with placebo were similar to those observed in the overall Inhibitors,research,lifescience,medical study population, but they were not KU-0063794 mouse statistically significant in this subgroup (Table 3). In the overall study population (with much larger sample sizes), these effect sizes were statistically significant. Discussion The primary objective of this subgroup analysis was to assess the tolerability associated Inhibitors,research,lifescience,medical with the initiation doses of paliperidone palmitate in this potentially sensitive patient population. The recommended initiation dosing for paliperidone palmitate requires use of the higher doses given 1week apart Inhibitors,research,lifescience,medical (150mgeq on day 1 and 100mgeq on day 8; 234 and 156mg respectively) in the deltoid muscle,

and is followed by once-monthly injections of 25–150mgeq (39–234mg). Published data show lower initial doses administered in the gluteal muscle can lead nearly to subtherapeutic plasma levels and poor longer-term response in schizophrenia [Gopal et al. 2010; Nasrallah et al. 2010]. Nonetheless, the recommended initial dosing may raise tolerability concerns for clinicians, particularly when managing patients early in the course of their illness where relatively low doses of antipsychotics are commonly preferred [McGorry and Group IEPAW, 2005; Schooler et al. 2005]. Thus, data presented here examined this issue. In this analysis, paliperidone palmitate at 150mgeq on day 1 and 100mgeq on day 8 (234 and 156mg respectively) was tolerated without any new or unexpected AEs in patients recently diagnosed with schizophrenia.